| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 CR-UK Institute for Cancer Studies, The University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK
2 German Cancer Centre, Department of Virus Associated Tumours, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
Correspondence
Alan Rickinson
A.B.Rickinson{at}bham.ac.uk
Epstein–Barr virus (EBV) infection and growth activation of human B cells is central to virus biology and disease pathogenesis, but is poorly understood in quantitative terms. Here, using virus at defined m.o.i., the different stages of this process at the single-cell level are followed in vitro. Virus binding to the B-cell surface, assayed by quantitative PCR, is highly efficient, particularly at the low m.o.i. values that most likely reflect physiologic events in vivo. However, only 10–15 % of bound virus genomes reach the cell nucleus, as visualized by sensitive fluorescence in situ hybridization (FISH) assay; viral genomes acquired per cell nucleus range from 1 to >10, depending on the m.o.i. Thereafter, despite differences in initial genome load, almost all nuclear genome-positive cells then go on to express the virus-encoded nuclear antigen EBNA2, upregulate the cell activation antigen CD23 and transit the cell cycle. EBNA2-positive cells in the first cycle post-infection then grow out to lymphoblastoid cell lines (LCLs) just as efficiently as do cells limiting-diluted from already established LCLs. This study therefore identifies EBV genome delivery to the nucleus as a key rate-limiting step in B-cell transformation, and highlights the remarkable efficiency with which a single virus genome, having reached the nucleus, then drives the transformation programme.
Details of virus quantification procedures and of experiments confirming the DNase resistance of EBV genomes in virus preparations are given in the Supplementary Information and the results of the quantification of EBV preparations in Supplementary Fig. S1, available as supplementary material in JGV Online.
This article has been cited by other articles:
|
|
 |
|
  C. Shannon-Lowe, E. Adland, A. I. Bell, H.-J. Delecluse, A. B. Rickinson, and M. Rowe Features Distinguishing Epstein-Barr Virus Infections of Epithelial Cells and B Cells: Viral Genome Expression, Genome Maintenance, and Genome Amplification J. Virol., August 1, 2009; 83(15): 7749 - 7760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Stamataki, C. Shannon-Lowe, J. Shaw, D. Mutimer, A. B. Rickinson, J. Gordon, D. H. Adams, P. Balfe, and J. A. McKeating Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells Blood, January 15, 2009; 113(3): 585 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chaganti, C. S. Ma, A. I. Bell, D. Croom-Carter, A. D. Hislop, S. G. Tangye, and A. B. Rickinson Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients Blood, August 1, 2008; 112(3): 672 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dorner, F. Zucol, C. Berger, R. Byland, G. T. Melroe, M. Bernasconi, R. F. Speck, and D. Nadal Distinct Ex Vivo Susceptibility of B-Cell Subsets to Epstein-Barr Virus Infection According to Differentiation Status and Tissue Origin J. Virol., May 1, 2008; 82(9): 4400 - 4412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tierney, J. Nagra, I. Hutchings, C. Shannon-Lowe, M. Altmann, W. Hammerschmidt, A. Rickinson, and A. Bell Epstein-Barr Virus Exploits BSAP/Pax5 To Achieve the B-Cell Specificity of Its Growth-Transforming Program J. Virol., September 15, 2007; 81(18): 10092 - 10100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Hutchings, R. J. Tierney, G. L. Kelly, J. Stylianou, A. B. Rickinson, and A. I. Bell Methylation Status of theEpstein-Barr Virus (EBV) BamHI W Latent Cycle Promoter and Promoter Activity: Analysis with Novel EBV-Positive Burkitt and Lymphoblastoid Cell Lines J. Virol., November 1, 2006; 80(21): 10700 - 10711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Kelly, A. E. Milner, G. S. Baldwin, A. I. Bell, and A. B. Rickinson Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells PNAS, October 3, 2006; 103(40): 14935 - 14940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Bornkamm, U. Behrends, and J. Mautner The infectious kiss: Newly infected B cells deliver Epstein-Barr virus to epithelial cells PNAS, May 9, 2006; 103(19): 7201 - 7202. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Shannon-Lowe, B. Neuhierl, G. Baldwin, A. B. Rickinson, and H.-J. Delecluse From the Cover: Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells PNAS, May 2, 2006; 103(18): 7065 - 7070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chaganti, A. I. Bell, N. B. Pastor, A. E. Milner, M. Drayson, J. Gordon, and A. B. Rickinson Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes Blood, December 15, 2005; 106(13): 4249 - 4252. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
